Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Natalia Elliot | February 17, 2025 | News story | Research and Development | Recce, Skin, diabetes, skin, skin infections
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including diabetic foot infections (DFI).
R327, a broad-spectrum antibiotic topical gel, was tested in a phase 2 open-label trial that evaluated its safety, tolerability, efficacy and plasma pharmacokinetics when applied directly to the infected area. It demonstrated a 93% primary efficacy endpoint over 14 days, and no serious adverse events.
ABSSSIs, including DFI necrotising fasciitis and post-operative wound infections, have a large healthcare burden, necessitating the use of antibiotics. Data from R327’s study aligns with the US Food and Drug Administration (FDA)’s aim to combat antimicrobial resistance (AMR).
Recce Pharmaceuticals director and chief medical advisor Dr Alan Dunton said, “Our robust data set, from pre-clinical, clinical and Australian Therapeutic Goods Administration special access scheme use cases, gives us confidence in the potential of our topical gel. These results reflect the broad-spectrum nature and rapid onset of effect of R327G, which positions us well for the upcoming phase 3 trials in Indonesia and Australia. Importantly, Recce has also demonstrated that its R327 anti-infective compounds are effective against diverse species of bacteria, including in vitro, against over 500 clinical isolates, many previously considered as drug-resistant.”
James Spargo
17/2/25
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Roche gains CE Mark for AI glucose monitoring system for diabetes management
Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous …
